AbCellera Biologics
ABCL
146 hedge funds and large institutions have $334M invested in AbCellera Biologics in 2024 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 45 increasing their positions, 39 reducing their positions, and 17 closing their positions.
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
22% more capital invested
Capital invested by funds: $275M → $334M (+$59.3M)
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
5% more funds holding
Funds holding: 139 → 146 (+7)
2.72% more ownership
Funds ownership: 35.85% → 38.56% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less call options, than puts
Call options by funds: $973K | Put options by funds: $1.3M
Top Buyers
| 1 |
Capital World Investors
Los Angeles,
California
|
+$22.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5.44M |
| 3 |
Millennium Management
New York
|
+$2.03M |
| 4 |
Two Sigma Investments
New York
|
+$2.02M |
| 5 |
Two Sigma Advisers
New York
|
+$1.2M |
Top Sellers
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$4.82M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.81M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.51M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$1.83M |
| 5 |
Renaissance Technologies
New York
|
-$1.28M |
ABCL Hedge Fund Activity: Q4 2024 in Review
146 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q4 2024, worth a combined $334M — up 22% from $275M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ABCL positions and 17 closed out — a net gain of 10 holders — while 45 added to existing stakes and 39 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $22.1M. The largest seller was Prosight Management, cutting an estimated $4.82M.
- 146 institutional investors held AbCellera Biologics (ABCL) as of Q4 2024, up from 139 in Q3 2024.
- Funds reported $334M of AbCellera Biologics stock for Q4 2024, up 22% quarter-over-quarter.
- 27 funds opened new AbCellera Biologics positions in Q4 2024 and 17 closed out, a net change of +10 holders.
- The largest AbCellera Biologics buyer in Q4 2024 was Capital World Investors, an estimated $22.1M added.
- The largest AbCellera Biologics seller in Q4 2024 was Prosight Management, an estimated $4.82M sold.
Based on aggregated 13F filings for Q4 2024.